혈액종양내과 임성희 교수

학력
2020.02	성균관대학교 박사
2015.02	성균관대학교 석사
2009.02	연세대학교 의과대학

경력
2025.03 ~현재	삼성서울병원 혈액종양내과 부교수
2024.03 ~ 2025.02	삼성서울병원 혈액종양내과 진료부교수
2023.03 ~ 2024.02	삼성서울병원 혈액종양내과 진료조교수
2019.03 ~ 2023.02	순천향대학교 부천병원 종양혈액내과 조교수
2017.03 ~ 2019.02	순천향대학교 부천병원 종양혈액내과 조교수1
2016.03 ~ 2017.02	한림대 동탄성심병원 혈액종양내과 임상강사
2014.03 ~ 2016.02	삼성서울병원 혈액종양내과 임상강사
2010.03 ~ 2014.02	삼성서울병원 내과 레지던트
2009.03 ~ 2010.02	연세대세브란스병원 인턴

ONCOL RES 2025 10.32604/or.2024.049054 Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab Kim, R; Park, JK; Kwon, M; An, M; Hong, JY; Park, JO; Lim, SH; Kim, ST

View PubMed

FRONT ONCOL 2024 10.3389/fonc.2024.1450732 TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice Shin, JE; Lim, SH; Lee, J; Lim, HY; Park, YS; Kim, ST

View PubMed

CANCERS 2024 10.3390/cancers16172969 The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer Lim, SH; Kim, MJ; Lee, J; Lim, HY; Kang, WK; Kim, ST

View PubMed

PATHOL RES PRACT 2024 10.1016/j.prp.2024.155473 Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis Choi, DH; Jang, HL; Lim, SH; Kim, ST; Hong, JY; Park, SH; Park, JO; Kim, DG; Kim, KM; Lee, J

View PubMed

WORLD J GASTRO ONCOL 2024 10.4251/wjgo.v16.i8.3521 Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1 Kang, SW; Lim, SH; Kim, MJ; Lee, J; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

CANCER RES TREAT 2024 10.4143/crt.2023.1226 Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study Lee, J; Lim, SH; Chung, JH; Song, W; Sung, HH; Jeong, BC; Park, SH

View PubMed

CANCER RES TREAT 2024 10.4143/crt.2024.015 Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies Cho, SW; Lim, SH; Kwon, GY; Kim, CK; Park, W; Pyo, H; Chung, JH; Song, W; Sung, HH; Jeong, BC; Park, SH

View PubMed

TRANSL CANCER RES 2024 10.21037/tcr-24-20 CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells Lim, SH; Lee, SY; Hong, JY; Lee, J; Kim, ST

View PubMed

CANCER LETT 2024 10.1016/j.canlet.2024.217041 The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial Lim, SH; Saluja, A; Vickers, S; Hong, JY; Kim, ST; Lavania, S; Pandey, S; Gupta, VK; Velagapudi, MR; Lee, J

View PubMed

BIOMATERIALS 2024 10.1016/j.biomaterials.2024.122504 Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer Ko, JH; Hyung, S; Heo, YJ; Jung, SM; Kim, ST; Park, SH; Hong, JY; Lim, SH; Kim, KM; Yoo, S; Li Jeon, N; Lee, JY

View PubMed

BMC CANCER 2024 10.1186/s12885-024-11972-w Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06) Lim, SH; Lee, KW; Kim, JJ; Im, HS; Kim, IH; Han, HS; Koo, DH; Cho, JH; Maeng, CH; Lee, MY; Lee, HJ; Kim, JH; Park, SG; Jung, JY; Shin, SH; Kim, KH; Kim, H; Oh, SY; Kang, MS; Jung, MKY; Rha, SY

View PubMed

BIOMEDICINES 2023 10.3390/biomedicines11123264 Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J

View PubMed

J GASTROINTEST ONCOL 2023 10.21037/jgo-23-598 The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer Jeon, Y; Lim, SH; Lee, J; Kang, WK; Jang, JY; Jeong, SY; Choi, D; Kim, ST

View PubMed

ONCOL RES 2023 10.32604/or.2023.030374 Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer Lim, SH; Cho, HJ; Kim, KM; Lim, HY; Kang, WK; Lee, J; Park, YS; Kim, HC; Kim, ST

View PubMed

ANTICANCER RES 2023 10.21873/anticanres.16607 Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study Lim, SH; Hong, JY; Park, JO; Park, YS; Kim, ST

View PubMed

J GASTROINTEST ONCOL 2023 10.21037/jgo-23-375 Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes Jang, JY; Jeon, YK; Jeong, SY; Lim, SH; Park, YS; Lim, HY; Lee, JY; Kim, ST

View PubMed

날짜					목 01	금 02	토 03	일 04	월 05	화 06	수 07	목 08	금 09	토 10	일 11	월 12	화 13	수 14	목 15	금 16	토 17	일 18	월 19	화 20	수 21	목 22	금 23	토 24	일 25	월 26	화 27	수 28	목 29	금 30	토 31
오전
오후

날짜	일 01	월 02	화 03	수 04	목 05	금 06	토 07	일 08	월 09	화 10	수 11	목 12	금 13	토 14	일 15	월 16	화 17	수 18	목 19	금 20	토 21	일 22	월 23	화 24	수 25	목 26	금 27	토 28	일 29	월 30
오전
오후

게재일	2014-10-22
발표년월	2012-05	구분	국내
학술지	가정의학회지
논문명(국문)
논문명(영문)
요약문	td	발행정보	2010;31(10):778-785
책임저자	이정권
저자	박주현, 이선진, 곽정임, 심재용, 이정권	제 1저자	박주현
초록첨부	test
논문첨부

혈액종양내과 임성희 교수

학력

경력